Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | NPY1R | P25929 | 3/20 | 0.41 |
| ▸ | NPY4R | P50391 | 3/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | TFPI | P10646 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31257027 | 0.94 | TFPI (0.42) | NPY5RNPY1RNPY4RTFPI | |
| SCHEMBL31265331 | 0.91 | NPY5R (0.44) | NPY5RNPY1RNPY4RSIRT2SIRT5 | |
| SCHEMBL29638080 | 0.91 | NPY4R (0.43) | NPY5RNPY1RNPY4RTFPINPY2R | |
| SCHEMBL29608915 | 0.89 | NPY4R (0.43) | NPY5RNPY1RNPY4RTFPINPY2R | |
| SCHEMBL29638076 | 0.88 | NPY4R (0.42) | NPY5RNPY1RNPY4RSIRT2SIRT5 | |
| SCHEMBL30198768 | 0.88 | NPY5R (0.41) | NPY5RNPY1RNPY4RSIRT2SIRT5 | |
| SCHEMBL29638063 | 0.87 | NPY4R (0.43) | NPY5RNPY1RNPY4RTFPINPY2R | |
| SCHEMBL8937002 | 0.86 | NMT2 (0.43) | NPY5RNPY1RNPY4RFURINNPY2R | |
| SCHEMBL8937021 | 0.86 | NMT2 (0.43) | NPY5RNPY1RNPY4RFURINNPY2R | |
| SCHEMBL29968300 | 0.86 | NPY4R (0.44) | NPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4591934-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4523749-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12214015-B2 | Use of c-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4019038-A2 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BioMarin Pharmaceutical Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220160836-A1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARMACEUTICAL INC. | 2022-05-26 | — | — | US | disclosed |